NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Sentiment: An improved post-analysis of late progression as pseudo or otherwise might repair the data in terms of PFS. However, because patients (are rumored) to not always go to (or continue) DCVax-L after progression, you could end up with some patients initially on DCVax-L that showed late progression and so gave up on DCVax-L when in fact the late progression was pseudo-progression, thus a sign that DCVax-L was working.

All this assumes that part of pseudo-progression determination is a believed limited window in which it can occur. This presumes that model was wrong. Maybe it was correct before DCVax-L, but is no longer correct.

I know this is rehash for you Sentiment. And Flipper and RK etc... . But I don't remember what you guys dug up about this window issue.